Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.77 |
| ▸ | HPGD | P15428 | 4/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | NGFR | P08138 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.63 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.63 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.63 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.63 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.63 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.63 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.63 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 7-Chlorokynurenic Acid SCHEMBL2680493 | 0.87 | HPGD (1.00) | MEN1KMT2AHPGDKDM4EMAPK1 | |
| SCHEMBL11698420 | 0.83 | NGFR (0.71) | MEN1KMT2AHPGDKDM4EMAPK1 | |
| SCHEMBL9441968 | 0.82 | GRIN1 (0.77) | MEN1KMT2AHPGDKDM4EMAPK1 | |
| SCHEMBL1503904 | 0.81 | HPGD (0.56) | MEN1KMT2AHPGDKDM4EMAPK1 | |
| SCHEMBL4516264 | 0.81 | NGFR (0.69) | MEN1KMT2AHPGDKDM4EMAPK1 | |
| SCHEMBL9452339 | 0.80 | NGFR (0.67) | MEN1KMT2AHPGDKDM4EMAPK1 | |
| SCHEMBL8210976 | 0.80 | NGFR (0.67) | MEN1KMT2AHPGDKDM4EMAPK1 | |
| SCHEMBL11615435 | 0.80 | NGFR (0.67) | MEN1KMT2AHPGDKDM4EMAPK1 | |
| SCHEMBL9452255 | 0.80 | NGFR (0.67) | MEN1KMT2AHPGDKDM4EMAPK1 | |
| SCHEMBL9452271 | 0.80 | NGFR (0.67) | MEN1KMT2AHPGDKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| CN-1826333-B | Diamine derivatives | DAIICHI SANKYO CO LTD | 2012-12-26 | — | — | CN | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| CN-1751025-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2006-03-22 | — | — | CN | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-5270309-A | Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders | MERCK SHARP & DOHME LIMITED (GB) | 1993-12-14 | — | — | US | disclosed |
| EP-0303387-B1 | KYNURENIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1993-04-21 | — | — | EP | disclosed |
| EP-0303387-A1 | Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders | MERCK SHARP & DOHME LTD. (GB) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | MEN1 457/4885KMT2A 3485/4885HPGD 2022/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | MEN1 457/4885KMT2A 3485/4885HPGD 2022/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | MEN1 457/4885KMT2A 3485/4885HPGD 2022/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | MEN1 1094/4885KMT2A 1453/4885HPGD 539/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | MEN1 602/4885KMT2A 3461/4885HPGD 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.